Peptide compounding policy reaches White House review—details still to come

An HHS/FDA document, the Interim Access Policy for Compounding Using Certain Peptides (RIN 0910-ZD94), is pending review at OIRA, the White House regulatory review office, which received it on October 14. A pending review is not a policy in effect. The public record names no peptides, so it does not confirm whether BPC-157, TB-500 or MOTS-c are covered, and as of October 16, no policy text had been published. Inside: what the record shows, what OIRA review means, and what to watch next. Official record: OIRA review entry, RIN 0910-ZD94.